NHS Framework Agreement for Proprietary Pharmaceuticals – Aflibercept and Ranibizumab ophthalmology products

Offer reference number: CM/PHR/17/5561

Period of framework agreement: 1.10.2018 – 30.9.2020 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

Products associated with the lots are listed on Document Nº 05 of the Invitation to Offer Each individual National Product Code (NPC) pack description in each of the regions is deemed to be a separate product for the application of the award criteria.

There is no restriction on the number of products that bidders can offer for, or be awarded.

The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.

The framework may also be used by private sector contractors and agents working on behalf of the above.